Elaine M. Hylek, MD
Professor
Boston University School of Medicine
Dept of Medicine
General Internal Medicine

MD, University of Pittsburgh School of Medicine
MPH, Harvard School of Public Health
MS, University of Pittsburgh



Expertise includes: Arterial Thrombosis; Venous Thrombosis; Atrial Fibrillation; Safety and Effectiveness of Antithrombotic Therapy.

Active Staff Privileges
Boston Medical Center
Medicine



2011-2011 Other: Awarded Best Doctors in America 2007, 2009, 2011


PERSONNEL AGREEMENT FOR RESEARCH SERVICES OF ELAINE M. HYLEK
01/01/2012 - 12/31/2013 (PI)
Department of Veterans Administration, Bedford

PERSONNEL AGREEMENT FOR RESEARCH SERVICES OF ELAINE HYLEK
01/01/2011 - 12/31/2013 (PI)
Department of Veterans Affairs

Phase II Study - Development and Implementation of Clinical Practice Guidelines in a Large Teaching Hospital for the Use of Fragmin as Bridging Therapy
07/01/2005 - 06/30/2007 (PI)
Pfizer, Inc.

Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) Registry
03/01/2005 - 02/28/2007 (PI)
Bristol-Myers Squibb

Differences in Baseline Patient Characteristics and Their Contribution to the Disparate Efficacy Conclusions of SPORTIF III and SPORTIF V
06/07/2005 - 12/06/2006 (PI)
AstraZeneca


Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement
02/16/2011 - 01/31/2017 (PI)
NIH-NHLBI
5R01 HL106029-05

Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation
09/30/2010 - 07/31/2015 (PI)
NIH-NINDS
5R01 NS070307-03

IPA Agreement - Guneet Jasuja
06/01/2013 - 08/31/2014 (PI)
VA

BRIDGE Trial
11/01/2009 - 10/31/2010 (PI)
Duke Clinical Research Inst NIH-NHLBI
U01 HL087229


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38. PMID: 30597497.
     
  2. Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2018 Nov 22. PMID: 30579505.
     
  3. Hylek EM. Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle. Thromb Haemost. 2018 Dec; 118(12):2018-2019. PMID: 30453349.
     
  4. Jackson LR, Kim S, Shrader P, Blanco R, Thomas L, Ezekowitz MD, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439. PMID: 30051164.
     
  5. Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 Oct 16; 138(16):1666-1676. PMID: 29871978.
     
  6. Hylek EM. Apixaban for End-Stage Kidney Disease. Circulation. 2018 Oct 09; 138(15):1534-1536. PMID: 30354524.
     
  7. Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. J Am Heart Assoc. 2018 Sep 18; 7(18):e008928. PMID: 30371218.
     
  8. Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2018 Sep 12. PMID: 30209126.
     
  9. O'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation. 2018 Aug 28; 138(9):889-897. PMID: 29678813.
     
  10. Jackson LR, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Singer D, Thomas L, Blanco R, Peterson ED, Piccini JP. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries. J Am Heart Assoc. 2018 Aug 21; 7(16):e008764. PMID: 30369317.
     
Showing 10 of 241 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 241 publications over 25 distinct years, with a maximum of 30 publications in 2014

YearPublications
19921
19941
19951
19961
19981
19991
20003
20013
20021
20036
20043
20052
20066
200710
200815
200911
20108
201118
20129
201321
201430
201524
201625
201719
201821
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Antithrombotic Therapy
Atrial Fibrillation
Intracranial Hemorrhage
Stroke
Thrombosis

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:


801 Massachusetts Ave Crosstown Center
Boston MA 02118
Google Map


Hylek's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department